Contractile responses to endothelin-1 are regulated by PKC phosphorylation of cardiac myosin binding protein-C in rat ventricular myocytes. 2018

Ioannis Smyrnias, and Normann Goodwin, and Dagmar Wachten, and Jonas Skogestad, and Jan Magnus Aronsen, and Emma L Robinson, and Kateryna Demydenko, and Anne Segonds-Pichon, and David Oxley, and Sakthivel Sadayappan, and Karin Sipido, and Martin D Bootman, and H Llewelyn Roderick
Babraham Institute, Babraham Research Campus, Babraham, Cambridge CB223AT, UK.

The shortening of sarcomeres that co-ordinates the pump function of the heart is stimulated by electrically-mediated increases in [Ca2+]. This process of excitation-contraction coupling (ECC) is subject to modulation by neurohormonal mediators that tune the output of the heart to meet the needs of the organism. Endothelin-1 (ET-1) is a potent modulator of cardiac function with effects on contraction amplitude, chronotropy and automaticity. The actions of ET-1 are evident during normal adaptive physiological responses and increased under pathophysiological conditions, such as following myocardial infarction and during heart failure, where ET-1 levels are elevated. In myocytes, ET-1 acts through ETA- or ETB-G protein-coupled receptors (GPCRs). Although well studied in atrial myocytes, the influence and mechanisms of action of ET-1 upon ECC in ventricular myocytes are not fully resolved. We show in rat ventricular myocytes that ET-1 elicits a biphasic effect on fractional shortening (initial transient negative and sustained positive inotropy) and increases the peak amplitude of systolic Ca2+ transients in adult rat ventricular myocytes. The negative inotropic phase was ETB receptor-dependent, whereas the positive inotropic response and increase in peak amplitude of systolic Ca2+ transients required ETA receptor engagement. Both effects of ET-1 required phospholipase C (PLC)-activity, although distinct signalling pathways downstream of PLC elicited the effects of each ET receptor. The negative inotropic response involved inositol 1,4,5-trisphosphate (InsP3) signalling and protein kinase C epsilon (PKCε). The positive inotropic action and the enhancement in Ca2+ transient amplitude induced by ET-1 were independent of InsP3 signalling, but suppressed by PKCε. Serine 302 in cardiac myosin binding protein-C was identified as a PKCε substrate that when phosphorylated contributed to the suppression of contraction and Ca2+ transients by PKCε following ET-1 stimulation. Thus, our data provide a new role and mechanism of action for InsP3 and PKCε in mediating the negative inotropic response and in restraining the positive inotropy and enhancement in Ca2+ transients following ET-1 stimulation.

UI MeSH Term Description Entries
D008297 Male Males
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D010738 Type C Phospholipases A subclass of phospholipases that hydrolyze the phosphoester bond found in the third position of GLYCEROPHOSPHOLIPIDS. Although the singular term phospholipase C specifically refers to an enzyme that catalyzes the hydrolysis of PHOSPHATIDYLCHOLINE (EC 3.1.4.3), it is commonly used in the literature to refer to broad variety of enzymes that specifically catalyze the hydrolysis of PHOSPHATIDYLINOSITOLS. Lecithinase C,Phospholipase C,Phospholipases, Type C,Phospholipases C
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D003600 Cytosol Intracellular fluid from the cytoplasm after removal of ORGANELLES and other insoluble cytoplasmic components. Cytosols
D006352 Heart Ventricles The lower right and left chambers of the heart. The right ventricle pumps venous BLOOD into the LUNGS and the left ventricle pumps oxygenated blood into the systemic arterial circulation. Cardiac Ventricle,Cardiac Ventricles,Heart Ventricle,Left Ventricle,Right Ventricle,Left Ventricles,Right Ventricles,Ventricle, Cardiac,Ventricle, Heart,Ventricle, Left,Ventricle, Right,Ventricles, Cardiac,Ventricles, Heart,Ventricles, Left,Ventricles, Right
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Ioannis Smyrnias, and Normann Goodwin, and Dagmar Wachten, and Jonas Skogestad, and Jan Magnus Aronsen, and Emma L Robinson, and Kateryna Demydenko, and Anne Segonds-Pichon, and David Oxley, and Sakthivel Sadayappan, and Karin Sipido, and Martin D Bootman, and H Llewelyn Roderick
May 2012, Journal of muscle research and cell motility,
Ioannis Smyrnias, and Normann Goodwin, and Dagmar Wachten, and Jonas Skogestad, and Jan Magnus Aronsen, and Emma L Robinson, and Kateryna Demydenko, and Anne Segonds-Pichon, and David Oxley, and Sakthivel Sadayappan, and Karin Sipido, and Martin D Bootman, and H Llewelyn Roderick
September 1997, The American journal of physiology,
Ioannis Smyrnias, and Normann Goodwin, and Dagmar Wachten, and Jonas Skogestad, and Jan Magnus Aronsen, and Emma L Robinson, and Kateryna Demydenko, and Anne Segonds-Pichon, and David Oxley, and Sakthivel Sadayappan, and Karin Sipido, and Martin D Bootman, and H Llewelyn Roderick
November 2005, Circulation research,
Ioannis Smyrnias, and Normann Goodwin, and Dagmar Wachten, and Jonas Skogestad, and Jan Magnus Aronsen, and Emma L Robinson, and Kateryna Demydenko, and Anne Segonds-Pichon, and David Oxley, and Sakthivel Sadayappan, and Karin Sipido, and Martin D Bootman, and H Llewelyn Roderick
November 2006, Proceedings of the National Academy of Sciences of the United States of America,
Ioannis Smyrnias, and Normann Goodwin, and Dagmar Wachten, and Jonas Skogestad, and Jan Magnus Aronsen, and Emma L Robinson, and Kateryna Demydenko, and Anne Segonds-Pichon, and David Oxley, and Sakthivel Sadayappan, and Karin Sipido, and Martin D Bootman, and H Llewelyn Roderick
January 2003, Methods in molecular biology (Clifton, N.J.),
Ioannis Smyrnias, and Normann Goodwin, and Dagmar Wachten, and Jonas Skogestad, and Jan Magnus Aronsen, and Emma L Robinson, and Kateryna Demydenko, and Anne Segonds-Pichon, and David Oxley, and Sakthivel Sadayappan, and Karin Sipido, and Martin D Bootman, and H Llewelyn Roderick
January 2014, Frontiers in physiology,
Ioannis Smyrnias, and Normann Goodwin, and Dagmar Wachten, and Jonas Skogestad, and Jan Magnus Aronsen, and Emma L Robinson, and Kateryna Demydenko, and Anne Segonds-Pichon, and David Oxley, and Sakthivel Sadayappan, and Karin Sipido, and Martin D Bootman, and H Llewelyn Roderick
September 2012, Circulation. Heart failure,
Ioannis Smyrnias, and Normann Goodwin, and Dagmar Wachten, and Jonas Skogestad, and Jan Magnus Aronsen, and Emma L Robinson, and Kateryna Demydenko, and Anne Segonds-Pichon, and David Oxley, and Sakthivel Sadayappan, and Karin Sipido, and Martin D Bootman, and H Llewelyn Roderick
August 2020, The Journal of biological chemistry,
Ioannis Smyrnias, and Normann Goodwin, and Dagmar Wachten, and Jonas Skogestad, and Jan Magnus Aronsen, and Emma L Robinson, and Kateryna Demydenko, and Anne Segonds-Pichon, and David Oxley, and Sakthivel Sadayappan, and Karin Sipido, and Martin D Bootman, and H Llewelyn Roderick
August 1996, Proceedings of the National Academy of Sciences of the United States of America,
Ioannis Smyrnias, and Normann Goodwin, and Dagmar Wachten, and Jonas Skogestad, and Jan Magnus Aronsen, and Emma L Robinson, and Kateryna Demydenko, and Anne Segonds-Pichon, and David Oxley, and Sakthivel Sadayappan, and Karin Sipido, and Martin D Bootman, and H Llewelyn Roderick
May 1997, Biochemical Society transactions,
Copied contents to your clipboard!